Sunday, May 29, 2016

Roth resumes coverage of Fibrocell at buy

Roth resumes coverage of Fibrocell at buy

May 24, 2016 by · Leave a Comment 

Tweet Roth Capital Partners has resumed coverage of Fibrocell Science (NASDAQ:FCSC) with a “buy” rating and $7 price target. The stock closed at $2.12 on Monday. Fibrocell leverages its expertise with fibroblasts to target diseases of the skin, connective tissue and joints. The technology can take advantage of the inherent properties of fibroblasts, but also […]

Roth adjusts DelMar Pharma price target to $12

Roth adjusts DelMar Pharma price target to $12

May 23, 2016 by · Leave a Comment 

Tweet Roth Capital Partners has adjusted its price target for DelMar Pharmaceuticals (OTCQX:DMPID) to $12 from $3 after the company’s 1-for-4 reverse stock split. The stock closed at $5.41 on Friday. Analyst Joseph Pantginis writes that the company’s net equity and operating funds are now sufficient to meet the goal of up listing to a […]

Roth ups Celator Pharma price target to $26

Roth ups Celator Pharma price target to $26

May 19, 2016 by · Leave a Comment 

Tweet Roth Capital Partners has raised its price target for Celator Pharmaceuticals (NASDAQ:CPXX) to $26 from $22, after the company’s Vyxeos drug candidate received breakthrough therapy designation from the FDA. The stock closed at $15.07 on Wednesday “This is an important next step for Vyxeos on the path to what we believe is likely approval,” […]

Roth reinitiates coverage of NeoGenomics at buy

Roth reinitiates coverage of NeoGenomics at buy

May 11, 2016 by · Leave a Comment 

Tweet Roth Capital Partners has reinitiated coverage on NeoGenomics with a “buy” rating and target price of $10, following its acquisition of Clarient from GE Healthcare. The stock closed at $8.34 on Tuesday. “We believe NeoGenomics is on the brink of demonstrating significant sales growth and operating leverage over the next several years as the […]

Roth starts Foundation Healthcare at buy

Roth starts Foundation Healthcare at buy

April 19, 2016 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of Foundation Healthcare (OTC:FDNH) with a “buy” rating and $6 price target. The stock closed at $3.05 on Monday. “The impetus for our buy rating is the potential of the company’s acquisition of University General Hospital (UGH) in Houston to drive increased EBITDA and EPS,” writes analyst Scott […]

FDA extends Probuphine action date

FDA extends Probuphine action date

February 19, 2016 by · Leave a Comment 

Tweet The FDA has extended its action date to consider approval of a NDA for Probuphine for the maintenance treatment of opioid addiction by the standard period to May 27 from Feb. 27. Following the Psychopharmacologic Advisory Committee meeting in January, which recommended approval of Probuphine, the FDA requested additional changes to the Risk Evaluation […]

Titan Medical offering raises $10.5-million

Titan Medical offering raises $10.5-million

February 12, 2016 by · Leave a Comment 

Tweet Titan Medical (OTCQX:TITXF; TSX:TMD) has closed a public offering of 11,670,818 units at a price of 90 cents each for gross proceeds of $10.5-million. Each unit consists of one common share and one warrant, with each warrant exercisable to purchase an additional common shares at a price of $1 for a period of 60 […]

Roth starts Bionomics at buy

Roth starts Bionomics at buy

February 3, 2016 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of Bionomics (OTCQX:BNOEF; ASX:BNO) with a “buy” rating and AUD$1.50 price target. The stock closed at 32 cents on Tuesday. “We believe a significant disconnect exists on the [company’s] BNC210 opportunity alone based on clinical data in hand and the partnering potential around a drug that could address […]

Roth starts TetraLogic Pharma at buy

Roth starts TetraLogic Pharma at buy

December 30, 2015 by · Leave a Comment 

Tweet Roth Capital Partners has launched coverage of TetraLogic Pharmaceutics (NASDAQ:TLOG) with a “buy” rating and price target of $5. The stock closed at $1.42 on Wednesday. Analyst Joseph Pantginis writes that TetraLogic is about to enter a critical time in its history. In January, the company is expected to report results of two Phase […]

Roth starts Prima BioMed at buy

Roth starts Prima BioMed at buy

December 30, 2015 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of Prima BioMed (NASDAQ:PBMD) with a “buy” rating and price target of $6. The stock closed at $1.11 on Wednesday. “We believe Prima is in a leading position in the development of new checkpoint inhibition pathways, based on the discovery of LAG-3 by Prima’s CMO/CSO,” writes analyst Joseph […]

Next Page »

Email Newsletters with Constant Contact
Google+